Pharmacological characterization of a novel 5-hydroxybenzothiazolone-derived b2-adrenoceptor agonist with functional selectivity for anabolic effects on skeletal muscle resulting in a wider cardiovascular safety window in preclinical studies

Koziczak-Holbro, Magdalena; Rigel, Dean F.; Dumotier, B�reng�re; Sykes, David A.; Tsao, Jeffrey; Nguyen, Ngoc Hong; B�sch, Julian; Jourdain, Marie; Flotte, Ludivine; Adachi, Yuichiro; Kiffe, Michael; Azria, Mo�se; Fairhurst, Robin A.; Charlton, Steven J.; Richardson, Brian P.; Lach-Trifilieff, Estelle; Glass, David J.; Ullrich, Thomas; Hatakeyama, Shinji

Abstract

Copyright ª 2019 by The Author(s) The anabolic effects of b2-adrenoceptor (b2-AR) agonists on skeletal muscle have been demonstrated in various species. However, the clinical use of b2-AR agonists for skeletal muscle wasting conditions has been limited by their undesired cardiovascular effects. Here, we describe the preclinical pharmacological profile of a novel 5-hydroxybenzothiazolone (5-HOB) derived b2-AR agonist in comparison with formoterol as a representative b2-AR agonist that have been well characterized. In vitro, 5-HOB has nanomolar affinity for the human b2-AR and selectivity over the b1-AR and b3-AR. 5-HOB also shows potent agonistic activity at the b2-AR in primary skeletal muscle myotubes and induces hypertrophy of skeletal muscle myotubes. Compared with formoterol, 5-HOB demonstrates comparable full-agonist activity on cAMP production in skeletal muscle cells and skeletal muscle tissue–derived membranes. In contrast, a greatly reduced intrinsic activity was determined in cardiomyocytes and cell membranes prepared from the rat heart. In addition, 5-HOB shows weak effects on chronotropy, inotropy, and vascular relaxation compared with formoterol. In vivo, 5-HOB significantly increases hind limb muscle weight in rats with attenuated effects on heart weight and ejection fraction, unlike formoterol. Furthermore, changes in cardiovascular parameters after bolus subcutaneous treatment in rats and rhesus monkeys are significantly lower with 5-HOB compared with formoterol. In conclusion, the pharmacological profile of 5-HOB indicates superior tissue selectivity compared with the conventional b2-AR agonist formoterol in preclinical studies and supports the notion that such tissue-selective agonists should be investigated for the safe treatment of muscle-wasting conditions without cardiovascular limiting effects.

Citation

Koziczak-Holbro, M., Rigel, D. F., Dumotier, B., Sykes, D. A., Tsao, J., Nguyen, N. H., Bösch, J., Jourdain, M., Flotte, L., Adachi, Y., Kiffe, M., Azria, M., Fairhurst, R. A., Charlton, S. J., Richardson, B. P., Lach-Trifilieff, E., Glass, D. J., Ullrich, T., & Hatakeyama, S. (2019). Pharmacological characterization of a novel 5-hydroxybenzothiazolone-derived b2-adrenoceptor agonist with functional selectivity for anabolic effects on skeletal muscle resulting in a wider cardiovascular safety window in preclinical studies. Journal of Pharmacology and Experimental Therapeutics, 369(2), 188-199. https://doi.org/10.1124/jpet.118.255307

• Journal Article Type: Article
• Acceptance Date: Feb 12, 2019
• Publication Date: May 1, 2019
• Deposit Date: Dec 13, 2019
• Publicly Available Date: Dec 16, 2019
• Journal: Journal of Pharmacology and Experimental Therapeutics
• Print ISSN: 0022-3565
• Electronic ISSN: 1521-0103
• Publisher: American Society for Pharmacology and Experimental Therapeutics
• Peer Reviewed: Peer Reviewed
• Volume: 369
• Issue: 2
• Pages: 188-199
• DOI: https://doi.org/10.1124/jpet.118.255307
• Keywords: Molecular Medicine; Pharmacology
• Public URL: https://nottingham-repository.worktribe.com/output/3180284
• Publisher URL: http://jpet.aspetjournals.org/content/369/2/188